Hematology: Is thalidomide combination a new option for myeloma?
Palumbo
Antonio
A
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D003907:Dexamethasone / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000379:methods; D006405:Hematology / Q000639:trends; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D013792:Thalidomide / Q000627:therapeutic use*; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000903:Antibiotics, Antineoplastic; D018931:Antineoplastic Agents, Hormonal; D013792:Thalidomide; D003907:Dexamethasone; D004317:Doxorubicin